国邦医药
(605507)
| 流通市值：70.36亿 | | | 总市值：130.32亿 |
| 流通股本：3.02亿 | | | 总股本：5.59亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 1,312,110,423.39 | 1,558,068,520.04 | 1,586,274,850.65 | 1,909,316,981.52 |
| 交易性金融资产 | 896,343,049.03 | 693,885,850.78 | 746,174,148.28 | 617,664,145.54 |
| 应收票据及应收账款 | 874,649,776.33 | 904,916,262.57 | 868,084,509.2 | 753,962,681.24 |
| 应收账款 | 874,649,776.33 | 904,916,262.57 | 868,084,509.2 | 753,962,681.24 |
| 应收款项融资 | 549,619,057.46 | 600,058,634.95 | 680,155,932.59 | 577,921,940.43 |
| 预付款项 | 443,505,620.17 | 697,759,039.64 | 890,661,497.96 | 584,003,692.86 |
| 其他应收款合计 | 16,592,208.3 | 12,494,164.69 | 24,120,954.18 | 17,973,643.49 |
| 存货 | 1,623,331,283.05 | 1,484,045,023.6 | 1,439,737,851.79 | 1,363,411,369 |
| 其他流动资产 | 36,046,302.41 | 35,833,803.55 | 26,001,689.29 | 50,045,354.05 |
| 流动资产合计 | 5,752,197,720.14 | 5,987,061,299.82 | 6,261,211,433.94 | 5,874,299,808.13 |
| 非流动资产: | | | | |
| 长期股权投资 | 95,806,310.18 | 98,544,246.69 | 100,614,916.17 | 102,573,725.12 |
| 其他非流动金融资产 | 20,000,000 | 20,000,000 | 10,000,000 | 10,000,000 |
| 投资性房地产 | 68,667,684.15 | 69,644,001.93 | 70,620,319.71 | 71,596,637.49 |
| 固定资产 | 3,960,696,003.56 | 3,972,211,789.89 | 3,994,442,822.16 | 4,088,394,980.75 |
| 在建工程 | 311,580,982.37 | 276,358,673.25 | 295,907,233.94 | 255,262,138.04 |
| 无形资产 | 344,588,660.03 | 346,229,605.7 | 348,344,120.14 | 350,834,698.02 |
| 商誉 | 25,487.37 | 25,487.37 | 25,487.37 | 25,487.37 |
| 长期待摊费用 | 7,096,286.9 | 7,213,784.33 | 7,331,281.76 | 7,448,779.19 |
| 递延所得税资产 | 10,801,239.23 | 12,529,946.78 | 8,742,429.38 | 8,959,660.91 |
| 其他非流动资产 | 7,922,465.04 | 18,273,797.46 | 17,443,911.97 | 11,040,252.56 |
| 非流动资产合计 | 4,827,185,118.83 | 4,821,031,333.4 | 4,853,472,522.6 | 4,906,136,359.45 |
| 资产总计 | 10,579,382,838.97 | 10,808,092,633.22 | 11,114,683,956.54 | 10,780,436,167.58 |
| 流动负债: | | | | |
| 短期借款 | 441,420,885 | 438,662,232 | 373,144,684.11 | 175,134,263.89 |
| 交易性金融负债 | - | - | 269,581 | 269,581 |
| 应付票据及应付账款 | 1,118,191,937.65 | 1,506,066,801.55 | 1,592,303,241.68 | 1,703,673,649.01 |
| 其中：应付票据 | 625,331,919.37 | 1,025,218,115.93 | 1,114,733,607.65 | 1,211,719,944.9 |
| 应付账款 | 492,860,018.28 | 480,848,685.62 | 477,569,634.03 | 491,953,704.11 |
| 合同负债 | 32,870,800.77 | 38,888,166.54 | 40,146,697.86 | 39,928,204.69 |
| 应付职工薪酬 | 77,516,367.91 | 90,779,039.56 | 58,292,453.02 | 99,428,621.14 |
| 应交税费 | 49,925,840.5 | 47,118,063.67 | 42,634,093.31 | 49,887,203.46 |
| 其他应付款合计 | 36,159,695.21 | 44,191,314.75 | 40,340,098.59 | 35,051,777.55 |
| 应付股利 | 621,951.39 | 621,951.39 | 621,951.39 | 621,951.39 |
| 一年内到期的非流动负债 | 37,980,000 | 40,328,445.54 | 342,613,236.24 | 452,167,378.46 |
| 其他流动负债 | 2,012,252.6 | 2,688,377.04 | 2,299,711.96 | 2,246,738.97 |
| 流动负债合计 | 1,796,077,779.64 | 2,208,722,440.65 | 2,492,043,797.77 | 2,557,787,418.17 |
| 非流动负债: | | | | |
| 长期借款 | 478,713,635 | 507,001,135.02 | 337,371,135.02 | 146,720,754.79 |
| 递延收益 | 23,443,243.6 | 24,397,606.98 | 18,192,080.92 | 16,673,826.65 |
| 递延所得税负债 | 5,872,816.14 | 6,590,000.88 | 7,800,792.28 | 7,196,919.34 |
| 非流动负债合计 | 508,029,694.74 | 537,988,742.88 | 363,364,008.22 | 170,591,500.78 |
| 负债合计 | 2,304,107,474.38 | 2,746,711,183.53 | 2,855,407,805.99 | 2,728,378,918.95 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 558,823,500 | 558,823,500 | 558,823,500 | 558,823,500 |
| 资本公积 | 3,607,669,769.18 | 3,607,669,769.18 | 3,608,933,503.18 | 3,608,933,503.18 |
| 减:库存股 | 111,130,875.89 | 111,130,875.89 | 8,520,226.04 | 1,479,452.95 |
| 盈余公积 | 212,760,772.14 | 212,760,772.14 | 212,760,772.14 | 212,760,772.14 |
| 未分配利润 | 4,003,526,709.5 | 3,788,853,659.08 | 3,883,279,031.14 | 3,668,301,959.82 |
| 归属于母公司股东权益合计 | 8,271,649,874.93 | 8,056,976,824.51 | 8,255,276,580.42 | 8,047,340,282.19 |
| 少数股东权益 | 3,625,489.66 | 4,404,625.18 | 3,999,570.13 | 4,716,966.44 |
| 股东权益合计 | 8,275,275,364.59 | 8,061,381,449.69 | 8,259,276,150.55 | 8,052,057,248.63 |
| 负债和股东权益合计 | 10,579,382,838.97 | 10,808,092,633.22 | 11,114,683,956.54 | 10,780,436,167.58 |
| 公告日期 | 2025-10-17 | 2025-07-30 | 2025-04-16 | 2025-03-28 |
| 审计意见(境内) | | | | 标准无保留意见 |